Ipamorelin vs Somatropin (HGH)
A side-by-side research comparison of Ipamorelin and Somatropin (HGH) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Ipamorelin | Somatropin (HGH) |
|---|---|---|
| Full name | Ipamorelin (Selective GH Secretagogue) | Recombinant Human Growth Hormone |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Prescription medication |
| Mechanism | Selectively activates GHSR on pituitary somatotrophs. Unlike GHRP-6 and hexarelin, does not significantly activate ACTH or prolactin-releasing pathways. | Binds to GH receptors on target cells, triggering the JAK2/STAT5 signaling pathway. Stimulates hepatic IGF-1 production, promotes protein synthesis, mobilizes fatty acids from adipose tissue, and increases glucose output. |
| Molecular weight | 711.9 Da | 22,124 Da |
| Half-life | 2 hours | 2-3 hours (subcutaneous); tissue effects persist 9-17 hours via IGF-1 |
| Bioavailability | High (SubQ) | ~80% subcutaneous |
| Typical dose | 100-300 mcg | 1-4 IU/day (anti-aging/wellness); 4-8 IU/day (performance) |
| Frequency | 1-3x daily | Daily (split AM/PM for higher doses) |
| Route | Subcutaneous injection | Subcutaneous injection |
Ipamorelin reported benefits
- Clean GH release
- No cortisol or prolactin increase
- Improved sleep
- Fat loss
- Joint support
- Anti-aging benefits
Somatropin (HGH) reported benefits
- Fat loss (especially visceral)
- Increased lean muscle mass
- Improved sleep quality
- Faster recovery from injury
- Improved skin elasticity
- Increased bone density
- Enhanced cognitive function
Related comparisons
Research and educational reference only. Not medical advice.